Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score

Detalhes bibliográficos
Autor(a) principal: Hering, Flavio Luis Ortiz [UNIFESP]
Data de Publicação: 2001
Outros Autores: Lipay, Mônica Vannucci Nunes [UNIFESP], Lipay, Marco Aurélio Silva [UNIFESP], Rodrigues, Paulo Roberto Teixeira [UNIFESP], Nesralah, Luciano José [UNIFESP], Srougi, Miguel [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S1516-31802001000400005
http://repositorio.unifesp.br/handle/11600/1200
Resumo: CONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers are not available and that effective treatment regimens forming hormone-resistant prostate cancers are yet to be developed. Among the most important regulators of apoptosis and programmed cell death is the bcl-2 gene and its related proteins. Elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy. OBJECTIVE: To characterize the expression of bcl-2 proteins as a prognostic factor in humans. DESIGN: A retrospective approach. SETTING: Urology section, Federal University of São Paulo. DIAGNOSTIC TEST USED: Immunohistochemical analysis using bcl-2 protein antibody and normal staining by hematoxylin-eosin. MAIN MEASUREMENTS: Prognostic relations and protein expression were evaluated considering the total sample (28) divided into two groups, high (8 to 10) and low (2 to 4), separated according to the histological differentiation grade (Gleason score) with 10 and 18 samples, respectively. RESULTS: The differentiation of grade into two groups separated according to the Gleason score in low and high types presented different bcl-2 expression (P < 0.001). CONCLUSION: The higher frequency of bcl-2 immunostaining in tumor samples was observed in association with more advanced Gleason scores and suggests that an increase in the ratio of this anti-apoptotic protein often occurs during progression of prostate cancers.
id UFSP_5a99d4774e7d7e3ddc72822ff32acc2a
oai_identifier_str oai:repositorio.unifesp.br/:11600/1200
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason scorebcl-2ProstateProstate adenocarcinomaApoptosisbcl-2PróstataAdenocarcinoma da próstataApoptoseCONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers are not available and that effective treatment regimens forming hormone-resistant prostate cancers are yet to be developed. Among the most important regulators of apoptosis and programmed cell death is the bcl-2 gene and its related proteins. Elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy. OBJECTIVE: To characterize the expression of bcl-2 proteins as a prognostic factor in humans. DESIGN: A retrospective approach. SETTING: Urology section, Federal University of São Paulo. DIAGNOSTIC TEST USED: Immunohistochemical analysis using bcl-2 protein antibody and normal staining by hematoxylin-eosin. MAIN MEASUREMENTS: Prognostic relations and protein expression were evaluated considering the total sample (28) divided into two groups, high (8 to 10) and low (2 to 4), separated according to the histological differentiation grade (Gleason score) with 10 and 18 samples, respectively. RESULTS: The differentiation of grade into two groups separated according to the Gleason score in low and high types presented different bcl-2 expression (P < 0.001). CONCLUSION: The higher frequency of bcl-2 immunostaining in tumor samples was observed in association with more advanced Gleason scores and suggests that an increase in the ratio of this anti-apoptotic protein often occurs during progression of prostate cancers.CONTEXTO: Diversos fatores genéticos e ambientais têm sido relacionados à oncogênese e progressão do câncer de próstata. A principal dificuldade na conduta clínica frente a esses tumores consiste no fato de não existirem marcadores prognósticos precisos, e que tratamentos eficazes dos tumores hormônio-resistentes não estão ainda disponíveis. Entre os reguladores mais importantes para avaliar a taxa de apoptose, destaca-se a expressão da proteína bcl-2. Os níveis elevados dessa proteína podem contribuir na progressão dos tumores prostáticos para um estado metastático e/ou hormônio independente, que caracteristicamente não apresenta resposta satisfatória ao tratamento quimioterápico. OBJETIVO: Investigar a expressão da proteína bcl-2 como fator prognóstico em portadores de tumores prostáticos. TIPO DE ESTUDO: Estudo retrospectivo. LOCAL: Disciplina de Urologia da Universidade Federal de São Paulo (UNIFESP). TESTE DIAGNÓSTICO: Exame anatomopatológico convencional por hematoxilina-eosina (HE) e imunohistoquímico. VARIÁVEIS ESTUDADAS: Expressão prognóstica da proteína bcl-2, por técnica imunohistoquímica em portadores de adenocarcinoma da próstata submetidos a prostatectomia radical. AMOSTRA: 28 amostras de tumores de próstata fixadas em parafina, provenientes de pacientes submetidos à prostatectomia radical sem ablação androgênica prévia, avaliadas por HE e por imunohistoquímica para a caracterização da expressão da proteína bcl-2. A expressão foi correlacionada ao grau de diferenciação do tumor, dividindo-se os tumores em dois grupos, segundo o escore de Gleason, em baixo (escore 2 a 4), e alto grau (8 a 10), sendo que os grupos foram divididos em 18 e 10 pacientes, respectivamente. RESULTADOS: Observou-se associação estatisticamente significativa (P < 0, 001) entre expressão elevada da proteína e os casos que apresentavam um escore de Gleason mais elevado (83, 3%), enquanto que no grupo de escore de baixo grau não foi detectada expressão da bcl-2 em 90% das amostras. CONCLUSÕES: O aumento na expressão da proteína bcl-2 em tumores de próstata com escore de Gleason elevado pode estar associado à progressão do adenocarcinoma de próstata.Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Department of SurgeryUNIFESP, EPM, Department of SurgerySciELOAssociação Paulista de Medicina - APMUniversidade Federal de São Paulo (UNIFESP)Hering, Flavio Luis Ortiz [UNIFESP]Lipay, Mônica Vannucci Nunes [UNIFESP]Lipay, Marco Aurélio Silva [UNIFESP]Rodrigues, Paulo Roberto Teixeira [UNIFESP]Nesralah, Luciano José [UNIFESP]Srougi, Miguel [UNIFESP]2015-06-14T13:29:26Z2015-06-14T13:29:26Z2001-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion138-141application/pdfhttp://dx.doi.org/10.1590/S1516-31802001000400005São Paulo Medical Journal. Associação Paulista de Medicina - APM, v. 119, n. 4, p. 138-141, 2001.10.1590/S1516-31802001000400005S1516-31802001000400005.pdf1516-3180S1516-31802001000400005http://repositorio.unifesp.br/handle/11600/1200engSão Paulo Medical Journalinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-04T12:53:37Zoai:repositorio.unifesp.br/:11600/1200Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-04T12:53:37Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
title Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
spellingShingle Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
Hering, Flavio Luis Ortiz [UNIFESP]
bcl-2
Prostate
Prostate adenocarcinoma
Apoptosis
bcl-2
Próstata
Adenocarcinoma da próstata
Apoptose
title_short Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
title_full Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
title_fullStr Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
title_full_unstemmed Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
title_sort Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
author Hering, Flavio Luis Ortiz [UNIFESP]
author_facet Hering, Flavio Luis Ortiz [UNIFESP]
Lipay, Mônica Vannucci Nunes [UNIFESP]
Lipay, Marco Aurélio Silva [UNIFESP]
Rodrigues, Paulo Roberto Teixeira [UNIFESP]
Nesralah, Luciano José [UNIFESP]
Srougi, Miguel [UNIFESP]
author_role author
author2 Lipay, Mônica Vannucci Nunes [UNIFESP]
Lipay, Marco Aurélio Silva [UNIFESP]
Rodrigues, Paulo Roberto Teixeira [UNIFESP]
Nesralah, Luciano José [UNIFESP]
Srougi, Miguel [UNIFESP]
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Hering, Flavio Luis Ortiz [UNIFESP]
Lipay, Mônica Vannucci Nunes [UNIFESP]
Lipay, Marco Aurélio Silva [UNIFESP]
Rodrigues, Paulo Roberto Teixeira [UNIFESP]
Nesralah, Luciano José [UNIFESP]
Srougi, Miguel [UNIFESP]
dc.subject.por.fl_str_mv bcl-2
Prostate
Prostate adenocarcinoma
Apoptosis
bcl-2
Próstata
Adenocarcinoma da próstata
Apoptose
topic bcl-2
Prostate
Prostate adenocarcinoma
Apoptosis
bcl-2
Próstata
Adenocarcinoma da próstata
Apoptose
description CONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers are not available and that effective treatment regimens forming hormone-resistant prostate cancers are yet to be developed. Among the most important regulators of apoptosis and programmed cell death is the bcl-2 gene and its related proteins. Elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy. OBJECTIVE: To characterize the expression of bcl-2 proteins as a prognostic factor in humans. DESIGN: A retrospective approach. SETTING: Urology section, Federal University of São Paulo. DIAGNOSTIC TEST USED: Immunohistochemical analysis using bcl-2 protein antibody and normal staining by hematoxylin-eosin. MAIN MEASUREMENTS: Prognostic relations and protein expression were evaluated considering the total sample (28) divided into two groups, high (8 to 10) and low (2 to 4), separated according to the histological differentiation grade (Gleason score) with 10 and 18 samples, respectively. RESULTS: The differentiation of grade into two groups separated according to the Gleason score in low and high types presented different bcl-2 expression (P < 0.001). CONCLUSION: The higher frequency of bcl-2 immunostaining in tumor samples was observed in association with more advanced Gleason scores and suggests that an increase in the ratio of this anti-apoptotic protein often occurs during progression of prostate cancers.
publishDate 2001
dc.date.none.fl_str_mv 2001-07-01
2015-06-14T13:29:26Z
2015-06-14T13:29:26Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S1516-31802001000400005
São Paulo Medical Journal. Associação Paulista de Medicina - APM, v. 119, n. 4, p. 138-141, 2001.
10.1590/S1516-31802001000400005
S1516-31802001000400005.pdf
1516-3180
S1516-31802001000400005
http://repositorio.unifesp.br/handle/11600/1200
url http://dx.doi.org/10.1590/S1516-31802001000400005
http://repositorio.unifesp.br/handle/11600/1200
identifier_str_mv São Paulo Medical Journal. Associação Paulista de Medicina - APM, v. 119, n. 4, p. 138-141, 2001.
10.1590/S1516-31802001000400005
S1516-31802001000400005.pdf
1516-3180
S1516-31802001000400005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv São Paulo Medical Journal
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 138-141
application/pdf
dc.publisher.none.fl_str_mv Associação Paulista de Medicina - APM
publisher.none.fl_str_mv Associação Paulista de Medicina - APM
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268281007112192